Drug Candidate Marketplace
Drug Candidate Marketplace lists the information of drug candidates, therapeutic targets and drug discovery technologies. Visitors can use search functions based on the interests and needs. If you have a drug candidates, therapeutic targets and drug discovery technologies that you are interested in and would like to gain more information, please contact us by clicking the inquiry button. After consenting to the terms of condition and use of our services, the requested information will be provided to you.
|Date||Candidate||Mechanism of action||Indication||Route||Development stage||Note|
|06/04/18||GEM020||3rd generation immunotherapy targeting little gastrin||Gastro-intestinal cancer （Pancreatic）||SC||Preclinical||-Applied 3rd generation immunotherapy technology to little gastrin.
-In-vivo POC has been validated in non-human primates.
|06/04/18||GEM019||3rd generation immunotherapy targeting HER2||HER2 overexpressing cancer （Breast）||SC||Preclinical||-Applied 3rd generation immunotherapy technology to HER2.
-Superior efficacy to trastuzumab and pertuzumab.
-In-vivo PoC has been validated in non-human primates.
|06/04/18||GEM018||3rd generation immunotherapy technology||Cancer||SC||Discovery||-Unique technology that triggers B and T cells simultaneously while activating all possible natural tumor killing mechanisms available to the immune-system.
-Tumor-directed specific activation reduces side effects to the minimum.
-Applicable on a target basis.
|05/31/18||GEM009||BET inhibitor||Cancer, Rheumatoid Arthritis||Oral||Preclinical||More potent activities and lower risk of cardiovascular toxicities than competitors||Contact|
|04/10/18||GEM008||Selective cMET inhibitor||NSCLC and HCC etc.||Oral||Phase 2||Effective on exon 14 skipping xenograft||Contact|
|03/26/18||GEM007||Vaccine||Anthrax||Oral||Discovery~ Preclinical||A cost-effective and safer vaccine that would produce immunity to anthrax with fewer doses||Contact|
|03/26/18||GEM006||Bacterial NADH production inhibitor||Bacterial infection||Discovery~ Preclinical||Inhibits synthesis of NADH in bacteria, but not in humans and expected to be used for treatment of multi-drug resistant pathogens||Contact|
|03/26/18||GEM005||Androgen receptor down-regulator||Prostate cancer||Discovery~ Preclinical||Decreases androgen receptor expression or function as well as androgen synthesis||Contact|
|03/26/18||GEM004||Actin polymerization blocker||Cancer||Discovery||Blocks actin polymerization by targeting an actin-associated protein and inhibits infiltration and metastasis||Contact|
|12/28/17||GEM003||Selective glucocorticoid receptor agonist||RA/OA||Local||Preclinical||Expected to reduce unfavorable responses of glucocorticoids by selectivity of action (transrepression>transactivation)||Contact|